Preliminary Amendm 2813-L

(New) A hematopoietic cell expansion media comprising cell growth media,

flt3-ligand and IL-6.

REMARKS

Applicants have amended the application to include new claims 50 to 55 which independently claim specific combinations of flt3-ligand with other cellular growth factors. Support for the amendment can be found at page 5, lines 15-23 of the specification. None of the specifically recited combinations is suggested or disclosed in the prior art of record. Indeed, since claims 36 and 49 have been considered allowable, applicants believe that the new claims 50 to 55 are allowable for the same reasons.

Respectfully Submitted

Stephen L. Malaska Attorney for Applicants Registration No. 32,655

Immunex Corporation Law Department 51 University Street Seattle, WA 98101

Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date listed below, and is addressed to BOX SEQUENCE, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signed: